Transparency Market Research

APD-209 to Record Fastest Growth in the Viral Conjunctivitis Pipeline Drugs Market During the Forecast Period

Transparency Market Research Report Added "Viral Conjunctivitis Pipeline Drugs Market" to its database.


Albany, NY -- (SBWIRE) -- 06/16/2016 -- Transparency Market Research has published a new market report titled, "Viral Conjunctivitis Pipeline Drugs Market - Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023". According to the report, the viral conjunctivitis pipeline drugs market is projected to reach US$ 0.5 Bn in 2023 at a CAGR of 69.6% from 2020 to 2023.

The viral conjunctivitis pipeline drugs market estimated in the report include FST-100 and APD-209, which are in phase II clinical trials. APD-209 is developed by Adenovir Pharma AB and is under phase II clinical trial. The company is likely to launch the drug in 2021. It has a patent in the EU, the U.S., China, Japan, Singapore, Russia, and Hong Kong for the treatment of epidemic keratoconjunctivitis (EKC). The phase II trials for keratoconjunctivitis have been completed in Sweden, Germany, and Poland. Targeted action for adenoviruses and safer than FST-100 are the major factors anticipated to drive the market for APD-209. However, narrow range of indication, long treatment duration as compared to FST-100, and launch of other medicines are likely to restrain the market during the forecast period from 2021 to 2023.

FST-100 is developed by New York-based Foresight Biotherapeutics, Inc. However, Shire plc acquired Foresight Biotherapeutics in July 2015. The company completed phase II clinical trial in May 2014 and Shire is expected to commence phase III clinical trial in 2016. It is a combination suspension of povidone-iodine and dexamethasone that targets microbial eradication along with anti-inflammatory action. If the drug is launched in 2020, it will have the first launch advantage in the market, as not a single drug is available in the market to treat viral conjunctivitis. However, presence of steroids in the formulation can lower the immunity of a patient and promote viral shedding, which can prolong symptoms. Hence, application of the drug for viral conjunctivitis is likely to be limited during the forecast period.

Other major drugs in pre-clinical and clinical trials are Zirgan (Bausch + Lomb, Inc. / Lifelong Vision Foundation), EKC-Cide (NanoViricides, Inc.), and PP-001 (Panoptes Pharma) to treat viral conjunctivitis.

Get a Sample of this Report:

Low diagnosis rate is a major restraint of the viral conjunctivitis pipeline drugs market. Most cases of conjunctivitis are diagnosed based on history and clinical examination. Hence, less than 50% of the cases are correctly diagnosed with the condition. However, AdenoPlus is a point of care test developed and manufactured by Rapid Pathogen Screening, Inc. (RPS). Sensitivity of this test is low; however, it is preferred in complicated cases. Hence, companies are recommended to tie up with diagnostic companies to develop and commercialize quick and accurate tests to diagnose various types of conjunctivitis.

The number of players operating in the viral conjunctivitis pipeline drugs market are limited, while demand for the therapy is high. Major players operating in the viral conjunctivitis pipeline drugs market are Adenovir Pharma AB, Allergan plc, NanoViricides, Inc., Shire plc, NovaBay Pharmaceuticals, Inc., Novartis AG, Panoptes Pharma GES.M.B.H., and NicOx S.A.

The viral conjunctivitis pipeline drugs market has been segmented as follows:

Viral Conjunctivitis Pipeline Drugs Market Revenue, by Pipeline Drug, (US$ Mn), Expected Launch–2023

FST-100 (2020-2023)
APD-209 (2021-2023)

Early Stage Preclinical Trials (Tabular Format)

Viral Conjunctivitis Pipeline Drugs Market Revenue, By Country, (US$ Mn), Expected Launch–2023


Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
NY - 12207
United States
Tel: 518-618-1030
USA - Canada Toll Free 866-552-3453